SEARCH

SEARCH BY CITATION

References

  • 1
    Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; January 11, 2010.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 3
    Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154: 319-328.
  • 4
    Museru OI, Vargas M, Kinyua M, Alexander KT, Franco-Paredes C, Oladele A. Hepatitis B virus infection among refugees resettled in the U.S.: high prevalence and challenges in access to health care. J Immigr Minor Health 2010; 12: 823-827.
  • 5
    Centers for Disease Control and Prevention. National, state and local area vaccination coverage among children aged 19-35 months—United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 1171-1177.
  • 6
    Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al.; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention. Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR Recomm Rep 2006; 55: 1-33.
  • 7
    Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis - United States, 2009. http://www.cdc.gov/hepatitis/Statistics/2009Surveillance.
  • 8
    Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188.
  • 9
    Centers for Disease Control and Prevention. Hepatitis C virus infection among persons 15-24 years. Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 537-541.
  • 10
    Rajendra A, Wong JB. Economics of chronic hepatitis B and hepatitis C. J Hepatol 2007; 47: 608-617.
  • 11
    Trust for America's Health/AASLD. HBV & HCV: America's Hidden Epidemics. Washington, DC: Trust for America's Health; 2010.
  • 12
    US Department of Health and Human Services. Combating the Silent Epidemic: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. Washington, DC: Department of Health and Human Services; 2011.
  • 13
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 14
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 15
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 16
    Bailey MB, Shiau R, Zola J, Fernyak SE, Fang T, So SK, et al. San Francisco hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer. J Community Health 2011; 36: 538-551.
  • 17
    Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; March 1, 2001.
  • 18
    Centers for Medicare and Medicaid Services. 2010 Physician Quality Reporting Index, Version 4.0. Published November 13, 2009. Accessed November 2011. http://www.cms.hhs.gov/PQRI/Downloads/2010_PQRI_MeasuresLIst_111309.pdf
  • 19
    Shehab TM, Sonnad S, Gebremariam A, Schoenfeld P. Knowledge of hepatitis C screening and management by internal medicine residents: trends over 2 years. Am J Gastroenterol 2002; 97: 1216-1222.
    Direct Link:
  • 20
    Willis BC, Wortley P, Wang SA, Jacques-Carroll L, Zhang F. Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus. Pediatrics 2010; 125: 704-711.
  • 21
    Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J 2011; 30: 575-579.
  • 22
    Fischer LR, Tope DH, Conboy KS, Hedblom BD, Ronberg E, Shewmake DK, et al. Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med 2000; 160: 1665-1673.
  • 23
    Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18: 474-481.
  • 24
    Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment–Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. HEPATOLOGY 2010; 52: 1124-1133.
  • 25
    Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-1525.
  • 26
    Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
  • 27
    Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. HEPATOLOGY 2007; 46: 1741-1749.
  • 28
    Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101: 2254-2262.
    Direct Link:
  • 29
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
  • 30
    Saag MS. Ryan White: an unintentional home builder. AIDS Read 2009; 19: 166-168.
  • 31
    Chu C, Selwyn PA. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urban Health 2011; 88: 556-566.
  • 32
    Landon BE, Hicks LS, O'Malley AJ, Lieu TA, Keegan T, McNeil BJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med 2007; 356: 921-934.
  • 33
    Wagner EH, Davis C, Schaefer J, Von Korff M, Austin B. A survey of leading chronic disease management programs: are they consistent with the literature? Manag Care Q 1999; 7: 56-66.
  • 34
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
  • 35
    Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat 2011; 18: 377-383.
  • 36
    Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
  • 37
    Kramer JR, Hachem CY, Kanwal F, Mei M, El-Serag HB. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. HEPATOLOGY 2011; 53: 42-52.
  • 38
    Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011; 154: 85-93.